GlassScriptPhysician profile
Mansi Singapori
NPI 1396240461
$961.01
in general payments reported to CMS, 2019-2025
15 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.28 · 2021: $58.65 · 2022: $20.94 · 2023: $108 · 2024: $36.70 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160.25 | 2025 | Talvey, Erleada, Balversa |
| Amgen INC. | $132.25 | 2025 | Blincyto |
| Seagen INC. | $108.43 | 2023 | Adcetris |
| Merck Sharp & Dohme LLC | $96.48 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Lilly USA, LLC | $71.00 | 2020-2025 | Verzenio |
| Gilead Sciences, INC. | $70.37 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $59.45 | 2025 | |
| Adc Therapeutics America, INC. | $58.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $55.94 | 2025 | |
| Springworks Therapeutics, INC. | $40.96 | 2025 | Ogsiveo |
| Pfizer INC. | $34.23 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.61 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.36 | 2025 | Enhertu |
| Emd Serono, INC. | $15.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansi Singapori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.